Skip to main content
. 2021 May 16;22(10):5247. doi: 10.3390/ijms22105247

Figure 7.

Figure 7

BMAL1-KD sensitizes CRC cell lines to oxaliplatin treatment. The sensitivity of CRC cells to oxaliplatin (LOH) drug was evaluated by the MTT cell viability assay. BMAL1-KD and their control cells were treated for 24 h to 48 h with increasing concentrations of LOH (from 12.5 to 75 μM). Cell viability after drug treatment is presented as a percentage relative to untreated cells. The mean values for three experiments are shown; error bars correspond to 95% confidence intervals. BMAL1-KD led to a distinct decrease in cell viability of HCT116 and SW480 cell lines under LOH treatment compared to their control cells, whereas no significant differences were observed with the metastasis SW620 cell line (n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001). Data are shown as means ± SEM.